ライフサイエンスコーパス: ocular toxicity

1 ated with a variety of toxicities, including ocular toxicity.

2 al human ND4 in murine mitochondria posed no ocular toxicity.

3 h doses, or their combination does not cause ocular toxicity.

4 ug cessation, and the risks for irreversible ocular toxicity.

5 osition as well as for signs of irreversible ocular toxicity.

6 systemic drugs that have been implicated in ocular toxicity.

7 tamoxifen use, including the possibility of ocular toxicity.

8 second cancers, and has few systemic and no ocular toxicities.

9 adhered well to the retina with no signs of ocular toxicities.

10 , and corneal changes as potential tamoxifen ocular toxicities.

11 Despite numerous case reports of ocular toxicity, a pharmacoepidemiological study of thei

12 sicians should be aware of the potential for ocular toxicity among patients receiving the drug and sh

13 vitro assays to obtain initial estimates for ocular toxicities and thus minimize the need for the Dra

14 In vivo bilateral topical ocular toxicity and antiviral efficacy were evaluated wi

15 uM SH-11037 was not associated with signs of ocular toxicity and did not interfere with retinal funct

16 ntation of monkeys with L or Z did not cause ocular toxicity and had no effect on biomarkers associat

17 astoma: they demonstrate low hematologic and ocular toxicity and no statistically significant influen

18 uded the number and severity of systemic and ocular toxicities, and vision loss >/=15 ETDRS letters.

19 We reviewed the literature for described ocular toxicities associated with both approved and inve

20 to establish causality, data from reports of ocular toxicity associated with systemic cidofovir (Vist

21 There were no signs of ocular toxicity at 1 year.

22 clinical series, and clinical trial data on ocular toxicities attributed to tamoxifen.

23 However, local ocular toxicities can be vision-threatening and long-ter

24 The 0.5% cidofovir exhibited the most ocular toxicity compared with FST-100, tobramycin/dexame

25 All patients with EMB ocular toxicity developed symptoms between outpatient cl

26 inhibition of CatD as a principal driver of ocular toxicity for BACE1 inhibitors and more generally

27 Ocular toxicity has been described with numerous approve

28 cataracts, glaucoma, retinopathy, and other ocular toxicities have been reported following chemother

29 en withdrawn from development after inducing ocular toxicity in animal models, but the target mediati

30 ll tolerated without evidence of systemic or ocular toxicity in participants with NVAMD.

31 ent in cells with the probe is predictive of ocular toxicity in vivo.

32 Ocular toxicity is the most important potential EMB toxi

33 Ocular toxicity is uncommon in the current clinical sett

34 Reports of drug-induced ocular toxicity must be well documented, and other cause

35 Because both of these agents induce ocular toxicity, novel inhibitors of autophagy with a be

36 No AMG 386-related ocular toxicities occurred, and no treatment-related cli

37 Subsequently, the ocular toxicities of six nonionic surfactants, Brij 700,

38 sent research was performed to ascertain the ocular toxicity of authentic lunar dust.

39 ome-based assay was developed for estimating ocular toxicity of surfactants.

40 stologic examination was performed to assess ocular toxicity of the delivery system.

41 and beta-toxin activity and demonstrates the ocular toxicity of these purified staphylococcal protein

42 The ocular toxicity of various compounds is typically determ

43 90 patients on intermittent therapy had EMB ocular toxicity (p = 0.05).

44 Ocular toxicities previously associated with pan-Hsp90 i

45 ival, ocular survival, hematologic toxicity, ocular toxicity, second cancer development and electrore

46 An ocular toxicity study was performed in dogs older than 1

47 EBM administration was associated with less ocular toxicity than daily EMB administration in this pa

48 Ocular toxicity was assessed and handled according to th

49 No evidence of ocular toxicity was detected after focally delivered Car

50 Ocular toxicity was evaluated by clinical findings and e

51 Ocular toxicity was evaluated by clinical findings and e

52 lation study, no histopathologic evidence of ocular toxicity was observed at any dose.

53 Transient ocular toxicities were observed after treatment, but mos

54 No other indications of ocular toxicity were observed.

55 6%) on daily therapy were diagnosed with EMB ocular toxicity, whereas 0 of 90 patients on intermitten

56 sustained intravitreal drug release without ocular toxicity, which may be useful to inhibit unwanted

57 oncologists to be aware of the potential for ocular toxicity, with prompt recognition of symptoms tha